✦ LIBER ✦

Doctors' participation in randomized trials of adjuvant systemic therapy in breast cancer: how does it relate to their recommendations for standard therapy in breast cancer?

✍ Scribed by P.M. Ellis; P.N. Buttow; R.J. Simes; M.H.N. Tattersall; S.M. Dunn; C. Macleod

Book ID: 114482546
Publisher: Elsevier Science
Year: 1999
Tongue: English
Weight: 51 KB
Volume: 8
Category: Article
ISSN: 0960-9776
DOI: 10.1054/brst.1999.0036

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Drug switch because of treatment-related

Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work?

✍ Uwe Güth; Mary Elizabeth Myrick; Andreas Schötzau; Nerbil Kilic; Seraina Margare 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 199 KB

Chemotherapy versus ovarian ablation as

Chemotherapy versus ovarian ablation as adjuvant therapy for breast cancer: impact on health-related quality of life in a randomized trial

✍ Mogens Groenvold; Peter M. Fayers; Morten Aagaard Petersen; Henning T. Mouridsen 📂 Article 📅 2006 🏛 Springer US 🌐 English ⚖ 623 KB

Toremifene is an effective and safe alte

Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials

✍ Wen-Bin Zhou; Qiang Ding; Ling Chen; Xiao-An Liu; Shui Wang 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 375 KB

Randomized adjuvant trial to evaluate th

Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer: 5-year results from the nishi-nippon group of the adjuvant chemoendocrine therapy for breast cancer organization

✍ Masakazu Toil; Takao Hattori; Masanobu Akagi; Kiyoshi Lnokuchi; Kunzo Orita; Kei 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 714 KB

Background. A randomized adjuvant trial was conducted from October 1982 to January 1985 to evaluate the addition of tamoxifen (TAM) to combination chemotherapy with perioperative mitomycin C (MMC) and ftorafur (FT) for patients with estrogen receptor (ER)-positive tumors and the addition of PSK, a b

P106 A Number-Needed-to-Treat(NNT) analy

P106 A Number-Needed-to-Treat(NNT) analysis of bonerelapse and mortality in a randomized trial of oral clodronate as supplementary adjuvant therapy for operable breast cancer

✍ T. Powles; A. Paterson; E. McCloskey; J. Kanis 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 162 KB